Penumbra, Inc.
PENHealthcareNASDAQMedical Devices · Last scanned Sep 8, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Penumbra, Inc. focuses on Medical Devices services and products. Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. At a $12.69B market cap, Penumbra, Inc. ranks as a large-cap company within healthcare. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.
Market Cap
$12.69B
Beta
0.70
P/E (TTM)
79.35
P/E (Fwd)
52.54
EPS (TTM)
$4.06
EPS (Fwd)
$6.13
ROE
11.4%
ROA
6.4%
Cash
$658.8M
Total Debt
$212.7M
Free CF
$161.1M
52W Change
12.2%
Annual Financials
Cash vs Debt
Where PEN stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, PEN finished 1.53% below its 150-day moving average ($327.80) and 0.40% below its 200-day moving average ($324.10). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is PEN overbought or oversold?
At the September 3, 2026 close, PEN's RSI(14) was 38.8, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $658.8M in cash and $212.7M in debt, PEN maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company generates $161.1M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 11.4% points to decent capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 6.4% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $847.1M (2022) to $1.40B (2025), reflecting a 66% increase over the period.
PEN's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. With cash comfortably exceeding debt, PEN has financial flexibility that may help navigate uncertain periods. At over 50x earnings, PEN carries valuation risk — any slowdown in growth expectations could lead to meaningful price adjustments. No single metric tells the full story. Reviewing PEN's risk profile alongside its fundamentals and technical indicators provides a more complete picture.